Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incyte Corp (NQ: INCY )

60.37 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 60.37
Bid (Size) 55.00 (3)
Ask (Size) 65.40 (4)
Prev. Close 60.37
Today's Range 60.37 - 60.37
52wk Range 58.54 - 86.29
Shares Outstanding 222,430,635
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Biotech Stocks That Should Be on Every Investor’s Radar This Fall
Even with higher for longer interest rates, drug discovery moves on. That’s why it’s still a good time to look for biotech stocks to buy. 
Via InvestorPlace
Pancreatic Cancer Battle Boosted by $200M VC Firm
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:MACK),(NASDAQ:INCY),(NASDAQ:MRTX),(NASDAQ:BNTX) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Exposures Death

Performance

YTD
-24.11%
-24.11%
1 Month
-6.95%
-6.95%
3 Month
-2.46%
-2.46%
6 Month
-16.45%
-16.45%
1 Year
-11.56%
-11.56%

More News

Read More
Anemia Advantage For GSK's Blood Cancer Therapy Could Influence Market Share Despite Incyte's Jakafi Comparison
Via Benzinga
Exposures Product Safety
Incyte Hits Five-Year Low After GSK Snags Approval For A New Jakafi Rival
Via Investor's Business Daily
Analyst Ratings for Incyte
Via Benzinga
Incyte's Earnings Outlook
Via Benzinga
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Incyte's Jakafi Patent Expiry In 2028 Poses Challenge, Analyst Says New Treatments To Battle For Market Share
Via Benzinga
Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte Corporation
Via Business Wire
Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
From Incyte
Via Business Wire
Cathie Wood's Ark Invest Buys Spotify, Iridium Shares — Trims Tesla, Coinbase Holdings
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 25, 2023
Via Benzinga
Syndax-Incyte Partnered Chronic Graft-Versus-Host Disease Achieves Primary Endpoint In Pivotal Trial, FDA Submission Planned By 2023 End
Via Benzinga
'I Don't Want You To Touch That': Cramer Rejects Stock Down 32% Over Past Month, Prefers Tesla
Via Benzinga
Incyte Skin Disease Drug Meets Primary Goal In Late-Stage Study In Children
Via Benzinga
Incyte Announces Positive Topline Results from Phase 3 Trial Evaluating Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis
From Incyte
Via Business Wire
Syndax Pharmaceuticals Set for Potential Breakthrough with Revumenib: Analyst Calls It 'Potentially Best-In-Class' In Competitive Landscape
Via Benzinga
Incyte to Report Second Quarter Financial Results
From Incyte
Via Business Wire
2 Low-Priced Stocks That Could Make You Richer
Via The Motley Fool
How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities
Via Talk Markets
Data from Across Incyte’s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress
From Incyte
Via Business Wire
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role
From Incyte
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023
Via Benzinga
Market Rally Finishes Strong; Regional Banks, Fed Rate Hike, Jobs Report, Apple In Focus: Weekly Review
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.